Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage-Reference-Cited by-同舟云学术

Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage

Published:2014-08-28 Issue:3 Volume:147 Page:609-616
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Chen Lu,Linden Hannah M.,Anderson Benjamin O.,Li Christopher I.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-014-3112-6.pdf

Reference44 articles.

1. Howlader N, Noone AM, Krapcho M, et al (2013) SEER cancer statistics review, 1975–2010. http://seer.cancer.gov/csr/1975_2010/ . Accessed 14 August 2014

2. Howlader N, Noone AM, Krapcho M, et al (2014) SEER cancer statistics review, 1975–2011. http://seer.cancer.gov/csr/1975_2010/ . Accessed 14 August 2014

3. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792

4. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52

5. Holleczek B, Brenner H (2012) Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany. BMC Cancer 12:317

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study;International Journal of Clinical Oncology;2024-02-04

2. Leveraging hypoxia in triple-negative breast cancer as a promising treatment strategy;Drug Discovery Today;2023-11

3. Resource‐appropriate evidence‐based strategies to improve breast cancer outcomes in low‐ and middle‐income countries guided by the Breast Health Global Initiative and Global Breast Cancer Initiative;Journal of Surgical Oncology;2023-10-09

4. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression;International Journal of Molecular Medicine;2023-07-19

5. PERSPECTIVEs on supervised exercise programs in people with metastatic breast cancer- a qualitative study in four European countries;Supportive Care in Cancer;2023-04-19